Vaccine Effectiveness Against the Delta and Omicron SARS-CoV-2 Variants

Primary immunization with the AstraZeneca, Moderna, or Pfizer vaccines provides minimal real-world protection against Omicron, with better protection afforded by booster immunization.

Prior work has shown that individuals who had completed the primary immunization series with the Moderna, Pfizer, or Johnson & Johnson COVID-19 vaccines all lacked neutralizing antibodies against the Omicron SARS-CoV-2 variant, although those who also received an mRNA vaccine booster dose did have detectable antibody titers (NEJM JW Infect Dis Feb 2022 and Cell 2021 Dec 23; [e-pub]. Still, real-world data on vaccine effectiveness (VE) against the newer SARS-CoV-2 variants remains limited. In a test-negative case-control study using data from the English National Immunization Management System, investigators assessed VE against symptomatic disease caused by Delta and Omicron. They compared the vaccination status of symptomatic individuals wh…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Vaccine Effectiveness Against the Delta and Omicron SARS-CoV-2 Variants

Topics

Reviewing Author